PolyMedix Inc. Receives $1.6 Million Contract from the Defense Threat Reduction Agency (DTRA) to Develop Antibiotic Compounds to Combat Biowarfare Pathogens

RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has received a research contract from the Defense Threat Reduction Agency (DTRA) in the amount of $1.6 million to develop new defensin-mimetic antibiotic compounds to combat biowarfare pathogens.